Skip to search formSkip to main contentSkip to account menu

CIGB-300

Known as: CK2-targeting Synthetic Peptide CIGB-300 
A synthetic peptide targeting the substrates of casein kinase 2 (CK2), with potential antineoplastic activity. Upon administration and nucleolar… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Casein-kinase CK2 is a Ser/Thr protein kinase that fosters cell survival and proliferation of malignant cells. The CK2 holoenzyme… 
Review
2019
Review
2019
CK2 genes are overexpressed in many human cancers, and most often overexpression is associated with worse prognosis. Site… 
Review
2018
Review
2018
Protein kinase CK2, formerly referred to as casein kinase II, is a serine/threonine kinase often found overexpressed in solid… 
Review
2018
Review
2018
CK2 is a ubiquitously expressed, constitutively active Ser/Thr protein kinase, which is considered the most pleiotropic protein… 
Review
2017
Review
2017
CK2 genes are overexpressed in many human cancers, and most often overexpression is associated with worse prognosis. Site… 
2015
2015
Background:We conducted a phase 1 trial in patients with locally advanced cervical cancer by injecting 0.5 ml of the CK2… 
2011
2011
CK2 represents an oncology target scientifically validated. However, clinical research with inhibitors of the CK2-mediated… 
2010
2010
CIGB-300 is a proapoptotic peptide-based drug that abrogates the CK2-mediated phosphorylation. This peptide has antineoplastic… 
Highly Cited
2009
Highly Cited
2009
CIGB-300, formerly known as P15-tat, is a proapoptotic peptide with established antiproliferative activity in vitro and… 
Highly Cited
2008
Highly Cited
2008
Protein Kinase CK2 is a serine-threonine kinase frequently deregulated in many human tumors. Here, we hypothesized that a peptide…